INKEF leads €64 million Series B financing round in Cardior

Photo: Dr. Clau­dia Ulbrich, Chief Execu­tive Offi­cer and Co-Foun­der of Cardior
31. August 2021

Berlin — INKEF Capi­tal led the consor­tium of inves­tors in the €64 million Series B finan­cing round invest­ment in Hano­­ver-based Cardior Phar­maceu­ti­cals. — In addi­tion to lead inves­tor INKEF, new inves­tors Fund+, Sunstone, Hadean Ventures and Copa­rion parti­ci­pa­ted in the round. In addi­tion, exis­ting inves­tors such as LSP, BioMed­Part­ners, Bris­tol Myers Squibb and High-Tech Grün­der­fonds also parti­ci­pa­ted in the finan­cing round. In connec­tion with the finan­cing, repre­sen­ta­ti­ves from INKEF, Fund+ and Sunstone will join the company’s advi­sory board.

Cardior Phar­maceu­ti­cals is a leading biophar­maceu­ti­cal company pionee­ring the disco­very and deve­lo­p­ment of RNA-based thera­peu­tics to prevent, treat and reverse heart dise­ase. The company’s mission is to provide pati­ents with novel thera­peu­tics and diagnostics that will have a lasting impact on the treat­ment of heart dise­ase worldwide.

“We believe ncRNAs can funda­ment­ally change the treat­ment of heart dise­ase by preven­ting, repai­ring and rever­sing damage to cardiac tissue. We thank our new and exis­ting inves­tors for their support and their confi­dence in our ability to achieve our goal,” said Dr. Clau­dia Ulbrich (photo), Chief Execu­tive Offi­cer and Co-Foun­­­der of Cardior.

INKEF Capi­tal is an Amster­­dam-based invest­ment fund with a port­fo­lio of more than 45 compa­nies in the health­care and tech­no­logy sectors.

Advi­sor INKEF + Inves­tor Consor­tium: YPOG
Dr. Martin Scha­per (Lead Part­ner), Partner
Dr. Malte Berg­mann, Partner
Dr. Martyna Sabat, Senior Associate
Dr. Ansgar Frank, Asso­cia­ted Partner
Ann-Kris­­tin Loch­mann, Senior Associate
Pia Meven, Associate
Jonas Huth, Associate
Lukas Schmitt, Associate

The law firm KNPZ (Dr. Kai Plath, Matthias Struck and Jan Schä­fer) advi­sed on the tran­sac­tion along­side the YPOG team in the IP area.

About YPOG

YPOG is a specia­list tax and commer­cial law firm, opera­ting in the core areas of corpo­rate, funds, liti­ga­tion, tax, tran­sac­tions, IT/IP and nota­rial services. The YPOG team advi­ses a wide variety of clients. These include emer­ging tech­no­logy compa­nies and family-run medium-sized enter­pri­ses as well as corpo­ra­ti­ons and private equity/venture capi­tal funds. Since its foun­da­tion in 2017, the firm has become one of the leading addres­ses for venture capi­tal, private equity and fund struc­tu­ring in Germany. The firm and its part­ners are natio­nally and inter­na­tio­nally ranked by JUVE, Best Lawy­ers, Legal 500, Focus, and Cham­bers and Part­ners. Today, YPOG employs more than 70 expe­ri­en­ced lawy­ers, tax advi­sors, tax specia­lists and a notary in three offices in Berlin, Hamburg and Colo­gne.

Subscribe newsletter

Here you can read about the latest transactions, IPOs, private equity deals and venture capital investments, who has raised a new fund, how Buy & Build activities are going.

Get in touch

Contact us!
fyb [at]